2015-2016 年北美和欧洲临床实验室分离的革兰氏阴性杆菌的体外药敏试验：SIDERO-WT-2015。
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
机构信息
International Health Management Associates, Inc., Schaumburg, Illinois, USA; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
International Health Management Associates, Inc., Schaumburg, Illinois, USA.
出版信息
Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22.
Cefiderocol (S-649266) is a parenteral siderophore cephalosporin in phase III of clinical development. In this study, we determined the in vitro susceptibility to cefiderocol and comparators of a 2015-2016 collection of 8954 clinical isolates of Gram-negative bacilli (GNB), provided by 100 clinical laboratories in North America and Europe, using the Clinical and Laboratory Standards Institute broth microdilution method. Iron-depleted cation-adjusted Mueller-Hinton broth was used to test cefiderocol. The concentration of cefiderocol inhibiting 90% of isolates (MIC) was 0.5 mg/L (North America; n=2470) and 1 mg/L (Europe; n=3,543) for Enterobacteriaceae, 0.5 mg/L (North America; n=619) and 0.5 mg/L (Europe; n=921) for Pseudomonas aeruginosa, 1 mg/L (North America; n=308) and 2 mg/L (Europe; n=664) for Acinetobacter spp., 0.5 mg/L (North America; n=165) and 0.25 mg/L (Europe; n=175) for Stenotrophomonas maltophilia, and 0.12 mg/L (North America; n=40) and 0.5 mg/L (Europe; n=49) for Burkholderia cepacia complex spp. Cefiderocol MICs were ≤4 mg/L for 99.9% (6005/6013) of Enterobacteriaceae, 99.9% (1539/1540) of P. aeruginosa, 96.4% (937/972) of Acinetobacter spp., 99.4% (338/340) of S. maltophilia, and 94.4% (84/89) of Burkholderia cepacia complex spp. isolates tested. Against meropenem-non-susceptible isolates, MICs to cefiderocol were ≤4 mg/L for 99.6% (245/246) of Enterobacteriaceae, 99.7% (394/395) of P. aeruginosa, 96.1% (540/562) of Acinetobacter spp., and 87.1% (27/31) of B. cepacia complex spp. We conclude that cefiderocol demonstrated potent in vitro activity (MIC ≤4 mg/L) against the majority (99.4%, 8903/8954) of clinical isolates of GNB in a recent (2015-2016), multi-continent collection, including carbapenem-non-susceptible isolates.
头孢他啶（S-649266）是一种处于临床开发 III 期的新型注射用铁载体头孢菌素。在本研究中，我们使用临床和实验室标准协会肉汤微量稀释法，对来自北美和欧洲 100 个临床实验室的 8954 株临床分离的革兰氏阴性菌（GNB），采用头孢他啶和其他比较药物进行了体外药敏试验。铁耗尽的阳离子调整的 Mueller-Hinton 肉汤用于检测头孢他啶。对肠杆菌科的头孢他啶抑制 90%的分离株（MIC）浓度为 0.5mg/L（北美；n=2470）和 1mg/L（欧洲；n=3543），对铜绿假单胞菌的 MIC 浓度为 0.5mg/L（北美；n=619）和 0.5mg/L（欧洲；n=921），对不动杆菌属的 MIC 浓度为 1mg/L（北美；n=308）和 2mg/L（欧洲；n=664），对嗜麦芽窄食单胞菌的 MIC 浓度为 0.5mg/L（北美；n=165）和 0.25mg/L（欧洲；n=175），对洋葱伯克霍尔德菌复合体的 MIC 浓度为 0.12mg/L（北美；n=40）和 0.5mg/L（欧洲；n=49）。99.9%（6005/6013）的肠杆菌科、99.9%（1539/1540）的铜绿假单胞菌、96.4%（937/972）的不动杆菌属、99.4%（338/340）的嗜麦芽窄食单胞菌和 94.4%（84/89）的洋葱伯克霍尔德菌复合体分离株的 MIC 值均≤4mg/L。对于美罗培南不敏感的分离株，MIC 值≤4mg/L 的有 99.6%（245/246）的肠杆菌科、99.7%（394/395）的铜绿假单胞菌、96.1%（540/562）的不动杆菌属和 87.1%（27/31）的洋葱伯克霍尔德菌复合体分离株。综上，头孢他啶对最近（2015-2016 年）多大陆采集的大多数（99.4%，8903/8954）革兰氏阴性菌临床分离株表现出强大的体外活性（MIC≤4mg/L），包括对碳青霉烯类药物不敏感的分离株。
Zotero 插件